Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort

Summary

This phase II trial studies the side effects of hypofractionated radiation therapy in treating patients with soft tissue sarcomas prior to surgery. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects.

Eligibility

Inclusion Criteria:

* Histologically confirmed soft tissue sarcoma of the extremity/trunk
* Intermediate or high grade sarcoma
* Resectable primary lesion (patients with pre-existing metastasis will be included if their primary is still going to be resected)
* Recurrent, any grade, no previous radiation therapy
* Karnofsky performance status (KPS) \>= 70 or Eastern Cooperative Oncology Group (ECOG) 0 - 2
* If a woman is of childbearing potential, a negative serum pregnancy test must be documented

Exclusion Criteria:

* Active treatment of a separate malignancy
* History of prior irradiation to the area to be treated
* Pre-operative chemotherapy (post-op acceptable)

Conditions2

Locations1 site

Browse More Trials